

Time window*	Overall mortality		Recurrent malignancy	
	HR (95% confidence interval)*	<i>P</i>	HR (95% confidence interval)*	<i>P</i>
90 days	0.88 (0.4 – 1.9)	.76	1.92 (0.9 – 4.3)	.11
180 days	1.23 (0.7 – 2.6)	.60	1.74 (0.8 – 3.9)	.18
1 year	1.68 (0.8 – 3.6)	.19	1.55 (0.7 – 3.4)	.28
2 years	2.25 (1.0 – 5.1)	.05	1.55 (0.7 – 3.4)	.28
Ever	2.22 (1.0 – 5.1)	.06	1.53 (0.7 – 3.4)	.30

* Since the duration or time window of possible MMF effect on risks of overall mortality or recurrent malignancy is not known, the analysis was carried out under a variety of assumptions. The analysis was stratified on the number of sites affected by chronic GVHD at onset (1 vs. >1) and the type of pre-transplant conditioning regimen (myeloablative vs. non-myeloablative).